Teva Pharmaceutical Industries Ltd.
TEVA | TA
Overview
Corporate Details
- ISIN(s):
- US8816242098 (+1 more)
- LEI:
- 549300BAFGM4RC74ZJ94
- Country:
- Israel
- Address:
- 124 DVORA HANEVIA, 6944020 TEL AVIV
- Website:
- https://www.tevapharm.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical company that develops, produces, and markets a dual portfolio of generic and innovative medicines. As one of the world's largest manufacturers of generic drugs, Teva focuses on making quality medications accessible and affordable globally. In parallel, the company develops and commercializes a portfolio of innovative and specialty products, with a focus on key therapeutic areas including the central nervous system (CNS)—targeting conditions like migraine, movement disorders, and schizophrenia—as well as immuno-oncology. Teva's integrated business model leverages its leadership in generics to support research and development of novel biopharmaceuticals to address unmet patient needs.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Teva Pharmaceutical Industries Ltd..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-06 01:14 |
Major Shareholding Notification
Immediate Report
|
English | 338.5 KB | |
| 2025-08-06 01:14 |
Foreign Filer Report
Immediate Report
|
English | 36.3 KB | |
| 2025-08-06 01:13 |
Major Shareholding Notification
Immediate Report
|
English | 340.1 KB | |
| 2025-08-06 01:13 |
Foreign Filer Report
Immediate Report
|
English | 36.3 KB | |
| 2025-07-31 01:15 |
Quarterly Report
FORM 10Q-FINANCIAL STATEMENTS -Q2/25
|
English | 352.1 KB | |
| 2025-07-31 01:15 |
Foreign Filer Report
FORM 10Q-FINANCIAL STATEMENTS -Q2/25
|
English | 36.5 KB | |
| 2025-07-30 16:15 |
Earnings Release
Reports 2025 Second Quarter Financial Results
|
English | 4.6 MB | |
| 2025-07-30 16:15 |
Foreign Filer Report
Reports 2025 Second Quarter Financial Results
|
English | 36.4 KB | |
| 2025-07-30 16:09 |
Regulatory News Service
The company's financial results for the second quarter 2025 reported abroad
|
Hebrew (modern) | 62.5 KB | |
| 2025-06-17 01:12 |
Director's Dealing
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Kalif Eliyahu…
|
English | 337.8 KB | |
| 2025-06-17 01:12 |
Foreign Filer Report
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Kalif Eliyahu…
|
English | 36.3 KB | |
| 2025-06-10 01:42 |
Director's Dealing
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Vergis Janet S
|
English | 337.4 KB | |
| 2025-06-10 01:42 |
Foreign Filer Report
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Vergis Janet S
|
English | 36.3 KB | |
| 2025-06-10 01:42 |
Director's Dealing
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Zaks Tal Zvi
|
English | 337.3 KB | |
| 2025-06-10 01:42 |
Foreign Filer Report
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Zaks Tal Zvi
|
English | 36.3 KB |
Automate Your Workflow. Get a real-time feed of all Teva Pharmaceutical Industries Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Teva Pharmaceutical Industries Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
